Please login to the form below

Not currently logged in
Email:
Password:

US pharma

This page shows the latest US pharma news and features for those working in and with pharma, biotech and healthcare.

Teva wins FDA OK for crucial migraine drug

Teva wins FDA OK for crucial migraine drug

Teva has secured US approval for migraine drug Ajovy, a key part of new chief execeutive Kåre Schultz's turnaround plan for the company. ... On balance, GlobalData is putting Aimovig out in front in 2026 given its first-mover advantage generating nearly

Latest news

  • Pfizer abandons antibody for Duchenne Pfizer abandons antibody for Duchenne

    The big pharma company halted two trials of the anti-myostatin antibody, which is designed to build muscle mass and strength. ... At the moment these are the only two drugs available to treat the underlying dystrophin gene mutation in some DMD patients,

  • Pfizer signs $425m flu vaccine deal with Germany’s BioNTech Pfizer signs $425m flu vaccine deal with Germany’s BioNTech

    Pfizer signs $425m flu vaccine deal with Germany’ s BioNTech. Pharma giant will take on development and commercial responsibility for candidates. ... The US pharma giant has just signed a front-loaded deal with BioNTech – with $120m in upfront and

  • Daily Brief: Summit's $12m lifeline, Biohaven's speech anxiety pill, Crescendo's Humabody progress Daily Brief: Summit's $12m lifeline, Biohaven's speech anxiety pill, Crescendo's Humabody progress

    UK specialist pharma company Summit Therapeutics has been awarded an extra $12m from a US government department to fund development of a new antibiotic. ... The US specialist pharma company has acquired rights to a wide-range of neurology candidates from

  • Confidence in UK’s post-Brexit healthcare sector on the wane Confidence in UK’s post-Brexit healthcare sector on the wane

    sector since the first quarter of 2018, according to Thomas Moore, GlobalData’s senior pharma analyst. ... Participants from the US were the least likely to have changed their sentiment, with 65% saying it had remained the same over the same time period

  • Allergan builds on gene editing deal Allergan builds on gene editing deal

    genes. The approach has been making the rounds quite recently in the pharma space, but this ground-breaking gene therapy is struggling to win over the FDA. ... Back in March, the US regulator halted Vertex Pharma’s planned trial involving CRISPR for

More from news
Approximately 8 fully matching, plus 487 partially matching documents found.

Latest Intelligence

  • A new era of smart pharma A new era of smart pharma

    A new era of smart pharma. How smarter pharmaceuticals and pharmacovigilance are transforming healthcare. ... Pharma companies are having to adapt and innovate to keep pace with the vast changes brought about by digital technology.

  • Six degrees of participation Six degrees of participation

    The era of Participatory Medicine - aka collaborative care or shared decision-making - is upon us, and fittingly for pharma, it’s the taking part that counts. ... UK, as well as the Head of Digital and therapeutic heads from within the pharma client

  • Health on instalment Health on instalment

    Health on instalment. Can US-style financial engineering underwrite ultra-expensive gene therapies? ... Given the animus that exists among US pharma stakeholders, reactions so far have been remarkably conciliatory.

  • Pharma deals continue to slide Pharma deals continue to slide

    Are deals being delayed or prevented by macroeconomic factors? Pfizer and some other big pharma companies are using uncertainty about US tax reform and Brexit and high company valuations as reasons ... 1, 410 (upfront 80). WuXi Biologics and Gloria

  • Macron, Merkel and May: implications of the 2017 elections for the life science industry Macron, Merkel and May: implications of the 2017 elections for the life science industry

    Being realistic, securing free trade deals with major economies such as the US, Japan and China could take a decade or more.

More from intelligence
Approximately 0 fully matching, plus 41 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 40 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics